Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Teva Pharma to purchase Mexico’s Rimsa for $2.3bn

Teva Pharma to purchase Mexico’s Rimsa for $2.3bn
The Rimsa purchase will contribute to Teva´s earnings starting from the first quarter of 2017.

Teva Pharmaceutical Industries (NYSE:TEVA) rose at midday after the Israeli generic drugs maker agreed to acquire Representaciones & Investigaciones Medicas SA, or Rimsa, for $2.3bn.

ADRs of Teva rose 1.6% to $57.37 at 11:23 a.m. in New York.

The Petah Tikva, Israel-based company said on Thursday Rimsa has an extensive portfolio of drugs, a promising drug pipeline and a well-established market presence to introduce additional Teva products in Mexico and Latin America.

Rimsa had $227mln in sales in 2014.

The purchase will contribute to Teva´s earnings starting from the first quarter of 2017. 

The transaction is expected to complete in the early part of 2016.

Goldman Sachs acted as financial adviser to the North American outfit in the sale.

 

View full TEVA profile View Profile

Teva Pharmaceutical Industries Timeline

Related Articles

GW_Pharma.png
June 07 2017
Midatech has three lead R&D programmes: a carcinoid syndrome treatment; a liver cancer drug; and a brain cancer therapy
woman at a microscope
September 04 2017
Lead product Lojuxta generated revenues of €5.75mln in the first-half

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use